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Abstract
Aims To select a core list of standard outcomes for diabetes to be routinely applied internationally, including patient-
reported outcomes.
Methods We conducted a structured systematic review of outcome measures, focusing on adults with either type 1 or
type 2 diabetes. This process was followed by a consensus-driven modified Delphi panel, including a multidisciplinary
group of academics, health professionals and people with diabetes. External feedback to validate the set of outcome
measures was sought from people with diabetes and health professionals.
Results The panel identified an essential set of clinical outcomes related to diabetes control, acute events, chronic
complications, health service utilisation, and survival that can be measured using routine administrative data and/or
clinical records. Three instruments were recommended for annual measurement of patient-reported outcome measures:
the WHO Well-Being Index for psychological well-being; the depression module of the Patient Health Questionnaire for
depression; and the Problem Areas in Diabetes scale for diabetes distress. A range of factors related to demographic,
diagnostic profile, lifestyle, social support and treatment of diabetes were also identified for case-mix adjustment.
Conclusions We recommend the standard set identified in this study for use in routine practice to monitor, benchmark
and improve diabetes care. The inclusion of patient-reported outcomes enables people living with diabetes to report
directly on their condition in a structured way.
Diabet. Med. 37, 2009–2018 (2020)
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Diabetes care aims to reduce diabetic complications and
improve quality of life. These goals should be continuously
monitored to ensure they are effective. The current focus on
clinical measurements, such as HbA1c, does not always
translate into better overall health [1,2]; therefore, there is a
need to measure the outcomes that matter most to people
with diabetes.
In this context, value-based healthcare is gaining momentum
by incorporating people’s needs into measures of utility gained
per unit cost [3]; however, the need to measure standardized
outcomes consistently over time and across clinical settings
presents a challenge to large-scale application of such healthcare
[4]. Countries differ in terms of medical practice, diagnostic
criteria and classification systems, making indicators difficult to
compare [5–7]. The same type of inconsistencies have also been
reported inclinical trials [8].Diabetes registrieshavebeenused to
overcome theaboveproblems,but their implementationhas also
been heterogeneous [9,10].
To facilitate the shift towards value-based healthcare, the
International Consortium for Health Outcomes Measure-
ment (ICHOM) aimed to identify measures reflecting the
concerns and experiences of people with diabetes.
The primary aim of the present study was to report the
standard set of outcomes that were identified as those that
mattered most to people with diabetes internationally,
including patient-reported outcome measures (PROMs). A
secondary aim was to define how often these outcomes
should be measured and which case-mix variables should be
used for risk adjustment.
Methods
The study was conducted between September 2017 and
August 2018 by a working group convened by the ICHOM.
The working group included people with diabetes and
experts from high- to low-income countries who had
published relevant work in this field.
Working group
The working group included 26 clinicians, scientists, epi-
demiologists and people with diabetes from six continents
(Table S1). All completed a conflict of interest form and code
of conduct agreement.
The working group agreed to target measures for adults
(aged ≥18 years) with type 1 or type 2 diabetes. Children/
adolescents were excluded because of their specific needs/
preferences, and people with gestational diabetes or sec-
ondary diabetes were excluded because of their specific
clinical characteristics.
The standard set of outcomes was developed after seven
plenary conference calls, conducted on the basis of a shared
agenda and background materials distributed by the project
team after structured literature reviews (Fig. 1). Several sub-
meetings were also conducted with working group members
to capture the perspective of people with diabetes or to seek
specific advice from field experts.
Literature search
A comprehensive systematic literature search was performed,
using key terms related to clinical outcomes, PROMs and
case-mix variables to extract papers published between 12
July 2007 and 12 July 2017 (Table S2). Documents (n=3555)
were selected either as a result of the search or from
additional sources, e.g. guidelines and materials from
diabetes registries (Tables S2 and S3). Two members of the
project team (J.N. and M.W.) independently screened all
articles for eligibility criteria to extract candidate items and
discuss them at each conference call until consensus was
reached.
Selection procedure
A modified Delphi approach was used to reach consensus on
the inclusion of the proposed outcomes (Fig. S1). Briefly,
working group members rated each item independently on a
Likert scale of 1 to 9 (1–3 = not important; 4–6 = nice to
have; 7–9 = very important). Items were included if rated 7–9
by at least 80% of the working group, or excluded if rated 1–
3 by 80% or below (Fig. S1). Inconclusive items were
presented for a second vote, along with the results of the first
What’s new?
• Standardized monitoring of diabetes care can improve
quality through routine audit and benchmarking.
Inconsistencies between measures adopted in different
countries hamper this process and undermine interna-
tional comparisons.
• This study was the first multinational effort to recom-
mend a standard list of outcomes that matter most to
people with diabetes, and that can be used in routine
clinical practice to monitor, benchmark and improve
diabetes care.
• The essential outcomes relate to diabetes control, acute
events, chronic complications, health service utilisation
and survival, measured using routine administrative
data and/or clinical records. Three instruments were
recommended for annual measurement of patient-
reported outcome measures (PROMs): the WHO
Well-Being Index for psychological well-being; the
depression module of the Patient Health Questionnaire
for depression; and the Problem Areas in Diabetes scale
for diabetes distress.
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round and additional documentation from the project team.
Items unresolved after the second round were discussed
jointly in an additional call, before being submitted to a final
vote where inclusion/exclusion was determined by a majority
rule.
The selection of outcomes was based on five criteria: 1)
importance to people with diabetes; 2) clinical relevance; 3)
sensitivity to changes in healthcare delivered; 4) feasibility of
capturing the outcome in clinical practice; and 5) validity
across cultures/internationally.
Thirty-three instruments for PROMs were selected out of
the 172 initially identified, based on their ability to cover
multiple dimensions. The final choice was based on descrip-
tions of tool properties available in an external database of
clinical outcome assessments (https://eprovide.mapi-trust.
org/about/about-proqolid), existing reviews (Table S2) and
psychometric properties referenced by the working group
(Table S4).
Case-mix variables were selected according to: 1) feasibil-
ity of collection in routine clinical care; 2) validation as a
case-mix variable (significantly associated with the outcomes
of interest and widely used); and 3) validity across settings/
regions/cultures.
The working group also agreed on time points for data
collection for each of the selected items.
Feedback from external stakeholders
The ICHOM obtained ethical approval for conducting an
online survey from the relevant institutional bodies in each
country. The recruitment of people with diabetes was carried
out via the ICHOM website and social media channels,
working group members’ professional networks and the
patient networks of the JDRF, USA and Imperial College
London Diabetes Centre, Abu Dhabi.
The final list of outcomes was reviewed by 128 people with
diabetes (type 1: n = 28; type 2: n=100) living in Mexico,
United Arab Emirates, the UK and the USA, who partici-
pated in a survey collecting comments through an anony-
mous online tool available in English, Spanish and Arabic.
Respondents were predominantly aged 18–65 years (86%),
and included slightly more women (59%). Most respondents
were actively treated with either insulin or non-insulin
therapy (94%), whilst the remaining group were on lifestyle
intervention (6%). Respondents were asked to rank selected
outcomes in order of importance, based on the same 1–9
Likert scale as that used by the experts, with an option to
mention additional outcomes in free text.
In addition, healthcare professionals (n=176) with an
interest in diabetes and/or outcome measures provided
feedback on the final draft of the standard set through a
separate online survey.
Ethics
No study in human or animal subjects was conducted for the
present paper, therefore, ethics committee approval was not
required.
Results
The final standard set of 27 outcomes was approved
unanimously by all members of the working group. Clinical
outcome measures were categorized into the domains
‘diabetes control’, ‘acute events’, ‘chronic complications’,
‘health services’ and ‘survival’ (Table 1), with defined time
FIGURE 1 Schematic overview of the project flow. PROMs, patient-reported outcome measures.
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points for data collection (Fig. 2). For detailed results, see
Tables S5–S8.
Diabetes control
For disease management, the working group recommended
including blood pressure, lipid profile, BMI and HbA1c,
without specifying target values. For HbA1c, the working
group extensively debated the timing of data collection: every
6 months was deemed appropriate for benchmarking. For
those on continuous glucose monitoring, the working group
considered including the percentage of time in range as an
informative measure [11].
Acute events
The working group recommended for their clinical rele-
vance the frequency of episodes of Diabetic Ketoacidosis,
Hyperosmolar Hyperglycaemic Syndrome, and Hypogly-
caemia recorded by any source. The working group adopted
level 2 and level 3 definitions of hypoglycaemia, consistent
with a recent publication of core outcomes in type 1
diabetes [11].
Chronic complications
The working group included conditions related to long-term
micro-/macrovascular complications. Autonomic neuropathy
was included for its association with sudden cardiovascular
death [12]. Peripheral neuropathy and peripheral artery
disease were both included and assessed using clinical
indicators and patient-reported symptoms. Peripheral artery
disease was defined as an ankle-brachial pressure index < 0.8
(if ankle-brachial pressure index is unavailable, the working
group recommended using the absence of pedal pulses) [13].
The working group also included ischaemic heart disease
and heart failure, according to the guidelines from the
American College of Cardiology and the American Heart
Association (ACC/AHA). The ACC/AHA guidelines consider
all people with diabetes to have at least stage A disease,
encouraging early intervention to prevent progression to
structural heart disease with symptoms [14].
For visual complications, the working group recommended
the adoption of two thresholds for visual acuity: (1) <20/40
for visual impairment, corresponding to a loss of sight that
hampers social participation, e.g. the right to drive; and (2)
<20/200 for severe visual impairment used by the WHO, also
an established criterion for legal blindness in many countries.
In addition, the working group recommended measuring
diabetic retinopathy, by class of severity, and macular
oedema. Other diabetes-related ocular pathologies, such as
cataract and glaucoma, were excluded because of their high
prevalence in the general population and scarce evidence to
suggest that tighter diabetes control might alter their natural
course.
The working group also recognized the relevance of
periodontal health with its documented association with
glycaemic control in people with diabetes [15]. As a standard
classification is still lacking for this often neglected compli-
cation, the working group suggested marking the presence of
‘healthy gums’, ‘gingivitis’ or ‘periodontitis’ at visits.
The working group also recommended reporting data on
erectile dysfunction. Concerning sexual dysfunction in
women, the working group acknowledged its presence but
could not identify a specific indicator for the standard set.
Lipodystrophy at injection sites was also included in the
outcomes set, given that it could affect the absorption of
subcutaneous therapy.
Health services
Three measures of health service utilisation were selected: the
number of hospitalizations per year; the number of emer-
gency department attendances per year; and discharge
diagnoses in major diabetes-related categories (cardiovascu-
lar, acute kidney injury, foot and lower limb-related
complications, acute metabolic diagnoses, and other/un-
known diagnoses) [16,17].
The working group also recommended: (1) collecting the
perceived financial barriers to care because of their impact on
determining a person’s ability to access care, especially in
countries without universal healthcare coverage; and (2)
assessing financial barriers using simple questions regarding
difficulties paying for healthcare.
Survival
The working group recommended using diabetes-related
deaths for the survival outcome. Being aware of the
limitations of data quality, particularly on death certificates,
the working group highlighted the need to record the cause
of death in order to attribute diabetes as a primary cause
more reliably.
Patient-reported outcome measures
The working group identified a set of key domains to be
captured using PROMs and that were important to people
with diabetes and those involved in clinical diabetes care.
These included self-reported health, mental health, impact
of diabetes on multiple aspects of quality of life, including
diabetes-related emotional distress, symptoms, treatment
burden and impact of hypoglycaemia. The group exten-
sively discussed and decided to prioritize the assessment of
well-being, depression and diabetes-related emotional dis-
tress. Starting with 33 tools initially identified by the
literature search, the working group conducted an in-depth
evaluation, followed by a discussion on a core selection of
eight generic and eight diabetes-specific tools in order to
identify tools that would provide the best possible domain
2012
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Table 1 Summary of the standard set of outcomes for diabetes
Measure Supporting information Timing of assessment Data source
Diabetes control
Glycaemic control HbA1c and time in range. Time in range is only
measured for people with diabetes who already
have access to continuous glucose monitoring
as part of their care
Baseline and 6-monthly Clinician/healthcare provider
Intermediate outcomes Includes disease management goals, such as






Diabetic ketoacidosis includes euglycaemic and
hyperglycaemic ketoacidosis
Baseline and 6-monthly Clinician/healthcare provider
Hypoglycaemia Level 2 hypoglycaemia is defined as a
measurable glucose concentration <54 mg/dl
(3.0 mmol/l) that needs immediate action. Level
3 hypoglycaemia is defined as a hypoglycaemic
event needing assistance





Presence of conditions Baseline and annually Clinician/healthcare provider or
person with diabetes
Lower limb amputation If more than one procedure in the past 12
months, state the most severe level
Baseline and annually Clinician/healthcare provider or
person with diabetes
Chronic complications
Autonomic neuropathy Presence of condition Baseline and annually Clinician/healthcare provider
Peripheral neuropathy Presence of condition Baseline and annually Clinician/healthcare provider
Charcot’s foot Presence of condition Baseline and annually Clinician/healthcare provider
Lower limb ulcers Presence of active lower limb ulcers; staging and
grading using the University of Texas wound
classification system
Baseline and annually Clinician/healthcare provider
Peripheral artery disease Evaluation of symptoms and clinical evidence
based on ankle-brachial-pressure-index < 0.8
or absence of pedal pulses
Baseline and annually Clinician/healthcare provider
Ischaemic heart disease Presence of condition Baseline and annually Clinician/healthcare provider or
person with diabetes
Chronic heart failure Stage of the condition according to the
American College of Cardiology/American
Heart Association criteria
Baseline and annually Clinician/healthcare provider
Chronic kidney disease and
dialysis
Readings of estimated glomerular filtration rate
and urinary albumin/creatinine
Baseline and annually Clinician/healthcare provider
Cerebrovascular disease Presence of condition Baseline and annually Clinician/healthcare provider
Vision Measurement of visual impairment (acuity) and
other diabetes-related sight-threatening
conditions
Baseline and annually Clinician/healthcare provider or
person with diabetes
Periodontal health If not healthy, specify whether gingivitis,
periodontitis or unknown
Baseline and annually Clinician/healthcare provider
Erectile dysfunction Only in men with diabetes Baseline and annually Clinician/healthcare provider or
person with diabetes
Lipodystrophy Only in people on injectable insulin or non-
insulin injectable therapies
Baseline and annually Clinician/healthcare provider
Health services





Number of emergency department attendances
in the past year
Annually Clinician/healthcare provider
Financial barriers to care Perceived financial barrier to care Annually Clinician/healthcare provider
Survival




Psychological well-being Captured using WHO-5 Baseline and annually Person with diabetes
Diabetes distress Captured using PAID Baseline and annually Person with diabetes
Depression Captured using PHQ-9 Baseline and annually Person with diabetes
PAID, Problem Areas in Diabetes; PHQ-9, Patient Health Questionnaire; WHO-5, WHO Well-Being Index.
A detailed definition of each outcome is provided in the online reference guide (available free at https://www.ichom.org/medical-conditions/
diabetes/).
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coverage, while fulfilling the requirements for brevity,
acceptability, validation and global availability (Tables S9
and S10).
At the end of this process, the working group selected two
generic and one diabetes-specific tool: the five-item WHO
Well-Being Index (WHO-5), the Patient Health Question-
naire-9 (PHQ-9) to measure depression, and the Problem
Areas in Diabetes (PAID) scale. Many pragmatic reasons
drove this selection, in particular, the instruments had to be
free for use in clinical practice and easily scored, preferably
by hand. Other factors that were considered were the
number of available translations, good psychometric prop-
erties and the domain coverage of the PROM. The PAID
scale was selected because of its broad coverage of the
diabetes-specific domains considered relevant by the working
group, despite not ranking highest in terms of psychometric
properties. A brief instrument such as PAID-5 was consid-
ered, but it offered a general level of diabetes-related distress
measure, without providing detailed insights. The PAID scale
has been validated in research and clinical settings and is
available in 17 languages. The instrument is a diabetes-
specific tool composed of 20 items measuring diabetes-
related emotional distress and a broad set of problem areas
often reported by people with type 1 or type 2 diabetes.
Scales such as the T1-Diabetes Distress Scale or others were
also discussed but were considered inferior to the PAID scale
as it represents a comprehensive measure for both types of
diabetes [18,19].
The WHO-5 tool assesses subjective mental well-being and
has been validated in both the general population and among
people with diabetes, with 31 translations available [20].
The working group adopted the PHQ-9 to measure
depression, as suggested from previous similar work [21].
The PHQ-9 scores each of the nine symptoms of major
depression according to the Diagnostic and Statistical Man-
ual of Mental Disorders to assess the severity of depressive
symptoms and response to treatment. The questionnaire has
been validated and made available in 79 translations [22].
While the WHO-5 has the advantage of being positively
worded (which may help in reducing response bias), it does
not map directly to the criteria for a diagnosis of depression
as the PHQ-9, which is essential for persuading healthcare
providers to take action and initiate treatment for depression.
However, a consensus was reached to maintain both ques-
tionnaires because of the significance of both in assessing
positive mental well-being as an indicator of quality of life
and depression symptoms in accordance with diagnostic
criteria [23].
In addition to the recommended PROMs, healthcare
providers may find it useful to adopt additional instruments
depending on their needs, considering the agreed key
domains.
Case-mix variables for risk adjustment
To enable fair comparisons across practices and/or geo-
graphical jurisdictions, 16 variables were included for case-
mix adjustment (Table 2). Several aspects were emphasized
during conference calls.
Regarding ethnicity, given the lack of standardized classi-
fications, the working group recommended criteria endorsed
by the International Diabetes Federation [24]. Level of
education was included as a surrogate for socio-economic
status. The working group decided to assess social support by
asking whom the person with diabetes lives with. With the
increasing role of social media as a source of support, the
working group might consider including this in future
iterations as well. For taking treatment, given the drawbacks
associated with existing questionnaires (expense and time
burden, and reliability/validity issues), the working group
selected key questions regarding advice from the healthcare
provider on diet, exercise, blood sugar monitoring, pre-
scribed medication and/or insulin use. Similarly, for access to
healthcare, questions were limited to ‘difficulties’ seeing a
healthcare provider or obtaining medication.
Feedback from external parties
In general, the online survey on the final list of outcomes
showed that people with diabetes ranked all included
FIGURE 2 Follow-up timeline of data collection for the diabetes standard set of outcomes.
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outcomes very highly. Interestingly, psychosocial outcomes
were ranked lower than visual and kidney complications,
circulation and lower limb amputations (Fig. S2, Table S8).
As this finding is not supported by the literature, various
sources of bias related to the composition of respondents, e.g.
selection bias, sample size or the effect of social desirability
might have influenced the result. Free-text responses showed
that access to treatment or equipment were also considered
important.
The online survey of health professionals and care
providers confirmed decisions of the working group on the
majority of outcomes. Concerns were expressed regarding
the feasibility and reliability of the following items: time in
range, hypoglycaemia level 3 and PROMs, reported via
questionnaires such as WHO-5 and PAID.
Discussion
In the present paper, we present the results of an ICHOM-led
initiative to deploy a standard set of outcomes, identified in a
scientific and collegial manner, as a means to monitor quality
of diabetes care routinely. To the best of our knowledge, this
is the first coordinated, multinational effort that achieves the
goal of standardizing the outcomes that most matter to
patients.
Previous efforts, such as the WHO International Classifi-
cation of Functioning, Disability and Health, focused
primarily on clinical considerations and were not necessarily
aligned with the views and primary concerns of people with
diabetes [25]. Other sets of outcomes proposed in clinical
practice were shown to be highly heterogeneous [26].
These results can facilitate the implementation of value-
based healthcare, as the set can be applied across practices
and jurisdictions such as local healthcare authorities,
provinces, regions and entire countries. This could be
relevant for international comparisons, as the same indica-
tors can now be applied consistently across federated
networks sharing a common infrastructure [9].
A fundamental output of this work includes the selection
of clinical outcomes that are still rarely reported in audits
and performance reports, such as hypo-/hyperglycaemic
events, periodontal health and erectile dysfunction.
Table 2 Summary of case-mix variables for the standard set of diabetes outcomes
Outcome domain/
measure Supporting information Timing of assessment Data source
Demographic factors
Sex Sex at birth Baseline Clinician/healthcare provider
Year of birth Calculate age Baseline Clinician/healthcare provider
Ethnicity This definition was based on categories in the
International Diabetes Federation consensus
Worldwide Definition of the Metabolic Syndrome
Baseline Person with diabetes
Education level Education level is based on the International Standard
Classification of Education




Diabetes type This set was developed with a focus on type 1 and type
2 diabetes. This will allow the two groups to be
analysed separately
Baseline Clinician/healthcare provider
Year of diagnosis The estimated year of diagnosis based on people with
diabetes’ estimate or clinical records
Baseline Clinician/healthcare provider
or person with diabetes
Comorbidities The reference guide contains a list of conditions Baseline and annually Clinician/healthcare provider
Lifestyle and social factors
Smoking Current status Baseline and annually Person with diabetes
Alcohol Consumption Amount and frequency Baseline and annually Person with diabetes
Physical Activity Being active is defined in accordance with the WHO
guidelines
Baseline and annually Person with diabetes
Social Support Whom the person with diabetes lives with Baseline and annually Person with diabetes
Treatment factor
Diabetes treatment Pharmacological or non-pharmacological therapy Baseline and annually Clinician/healthcare provider
Blood pressure-lowering
therapy
Report on treatment Baseline and annually Clinician/healthcare provider
Statins/lipid-lowering
therapy
Report on treatment Baseline and annually Clinician/healthcare provider
Taking treatment Not validated: use with caution. The questions on this
domain rate how well the individual sticks to advice
on diet, exercise, blood sugar monitoring and
prescribed medication.
Baseline and annually Person with diabetes
Access to healthcare Assesses the level of difficulty (and reasons) in accessing
healthcare professionals or obtaining medicines or
other medical supplies
Baseline and annually Person with diabetes
A detailed definition of each case-mix variable is provided in the online reference guide (available free at https://www.ichom.org/medical-
conditions/diabetes/).
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As far as PROMs are concerned, we identified mental well-
being, diabetes distress and depression as the key domains
that should be monitored on a regular basis. The reliability
and interpretation of these measures, particularly for psy-
chosocial factors, is still largely debated [27]. Reportedly,
only 10% of diabetes clinical trials used PROMs to take
preferences and values of people with diabetes into account.
The inclusion of selected PROMs in our standard set aligns
with recent recommendations for patient-centred manage-
ment of hyperglycaemia [28] and clinical diabetes manage-
ment [29]. The selected WHO-5, PHQ-9 and PAID are well-
established instruments with only a few items.
For case-mix, the working group identified demographic
and clinical characteristics to be used for risk adjustment, so
that fair comparisons can be correctly carried out ex post.
The specification of time intervals at which data items
should be collected is considered key to ensuring the
actionability of the standard set. For data collection, the
working group indicated the intervals should be: time zero
(baseline); 6 months (outcomes related to diabetes control);
and annually (with all other variables, with the exception of
general education status, to be measured every 5 years).
The implementation of the standard set may be challeng-
ing, but the implementing teams can learn from the many
success stories of routine data collection in diabetes around
the world [30].
The content of the standard set of outcomes may not
completely overlap with data elements available in existing
data sources; however, in many cases, they can be either
adapted or mapped directly to the existing databases. The
experience of the specialized international EUBIROD net-
work shows the shared development of analytical platforms
can speed up harmonization through collaboration and
mutual learning [31,32].
In more complex situations, data collection systems may
need to be substantially upgraded or built from scratch with
dedicated investment. In these cases, the active participation
of local stakeholders will be key to overcoming many
existing barriers.
Several registries have already reported the routine use of
PROMs [33], while others are still in their experimental
phase. The most advanced permanent data collection is
currently run in Sweden, where the majority of data elements
included in the set can be derived through linkage across
quality registries yy[34,35].
The most advanced experiences of data collection in
diabetes show that systematic data collection of multidimen-
sional items requires specific policies and clear governance
mechanisms. Introducing the standard set of outcomes in
everyday practice, be it a single provider or a regional area,
may have significant costs in terms of human resources,
which may not be easy to cover. Moreover, countries have
different cultures and very diverse information systems, so
the application of best practice, for example, linked elec-
tronic health records, may not always be reproducible.
Further research is needed, to make sure that implemen-
tation is matched by better evidence on the use of all data
elements in everyday practice, particularly for PROMs.
We need to know more about their properties in terms of
patient acceptability, feasibility across different patient
subgroups and the ethical implications of administering
questionnaires that can inadvertently cause undesired conse-
quences when exploring scales included in the standard set,
for example, depression.
As language and framing of diabetes at clinical care encoun-
ters are of substantial importance to people with diabetes and
their caregivers, we need to understand better how outcome
measures have an impact on their life at different stages of the
disease.Thiswill require involvingpeoplewithdiabetesdirectly
in the evaluation of PROMs, particularly as they will be
requested to consent on data collection on a routine basis.
To help with implementation, ICHOM has provided a
summary reference guide for general use, including details of
all items in the data dictionary and recommended timelines
for data collection (http://www.ichom.org/medical-conditions/
diabetes/).
For next steps, ICHOM plans to establish a Steering
Committee including selected working group members to
progress the following phases: (1) preparation: engaging
clinical leaders and people with diabetes to create multidis-
ciplinary teams governing the process; (2) diagnosis: exam-
ining data flows and identifying gaps that must be resolved to
strengthen the information infrastructure; (3) roll-out, to
pilot data collection; and (4) measurement, to apply the
standard set, perform statistical analyses and gather feed-
back. As the standard set will provide a broader basis for
permanent data collection, long-term implementation must
be the goal, including the need for regular updates and
continuous improvement to the set.
Finally, some limitations of the present study are worth
outlining. Firstly, the production of the standard set of
outcomes was based on the professional opinion of a limited
group of experts. Nonetheless, many of the experts work
directly (e.g. provide care) or indirectly (e.g. conduct qualita-
tive interviews) with people with diabetes so their views are
informed. Further, the working group included the most
relevant types of stakeholders, including people with diabetes.
Secondly, feedback received frompeoplewith diabetes came
froma small sample originating from four high-income/upper-
middle-income countries. In lower-income countries, manag-
ing diabetes is more complex, with scarce resources and
varying degrees of literacy, which might call into question the
applicability of the recommended measures. Nevertheless, the
relevance of included domains for lower-income countries was
also taken into account in the selection process.
Thirdly, the working group acknowledged that challenges
in the management of type 1 diabetes differ significantly from
those of type 2 diabetes. As such, there might well be
differences in the relative importance of selected outcomes
and PROMs. The final selection leaves room for type-specific
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measures that stakeholders may wish to consider, whenever
appropriate. The fact that both types of diabetes are lifetime
conditions with a multitude of possible and variable combi-
nations of different comorbidities, other therapies and socio-
economic contexts may also hamper an objective comparison
of the results obtained by applying this set.
Finally, thechoiceofspecificPROMswasmadeonpragmatic
grounds, including their accessibility and acceptability in
different settings. We cannot ensure that the standard set can
be uniformly applied across providers and systems under
different arrangements, e.g. insurance- vs national-driven
health systems. Future work is needed to clarify the details of
implementation under different conditions.
In conclusion, the ICHOM diabetes working group deliv-
ered a core set of patient-centred outcomes perceived to be
most important for individuals with diabetes. The standard
set is recommended for use in clinical practice. Its wide
adoption can help improve monitoring and benchmarking of
quality and outcomes in diabetes across clinical settings and
jurisdictions. Further studies are needed to evaluate the
results of its implementation formally and to update the
dictionary with feedback from a broader audience.
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